Published in Gene Therapy Weekly, March 24th, 2005
"Cancer gene therapy for the treatment of lung cancer has shown promise in the laboratory and in phase I/II clinical trials. However, it is currently limited to treating localized tumors due to host-immunity against the gene delivery vector and the transgene. Therefore, there is a tremendous effort to develop and test alternate gene delivery vectors that are efficient, non-immunogenic, and applicable for systemic therapy," scientists writing in the journal Technology in Cancer Research & Treatment report.
"One such gene delivery vehicle is the non-viral vector,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.